Antiprogestins for Contraception?

ABSTRACT

Antiprogestins could be a very promising group of compounds for contraception because they counteract the effects of progesterone, a key hormone for normal reproductive functioning. Great efforts have therefore been devoted to testing various ways of using these compounds for family planning. Most of this work has involved mifepristone; other antiprogestins have not been available for trials. With a few exceptions, the outcome of the studies performed to date has not met expectations. The most promising approaches seem to be the use of antiprogestins for emergency contraception, perhaps also as a daily pill when the dose is high enough to block ovulation, and in sequential regimens followed by a progestin. Given that antiprogestins differ in their affinity for target organs, better results could possibly be achieved by using more specific compounds than mifepristone. It is hoped that a wider choice of antiprogestational compounds will soon become available for research.

KEYWORDS

Antiprogestins - mifepristone - contraception - emergency contraception

REFERENCES

• 1 United Nations .World Contraceptive Use 2003. New York; United Nations 2004
• 2 Shah I H. Perspectives of users and potential users on methods of fertility regulation. In: Puri CP, Van Look PFA Sexual and Reproductive Health-Recent Advances and Future Directions. Vol II New Delhi; New Age International (P) Ltd. 2001: 45-92
• 3 World Health Organization .Improving Access to Quality Care in Family Planning-Medical Eligibility Criteria for Contraceptive Use 3rd ed. Geneva; Department of Reproductive Health and Research World Health Organization 2004
• 4 Wang C, Sinha-Hikim A, Leung A. The anti-progestin CDB 2914 has no antifertility effect in male rats.  Contraception. 1995;  51 215-218
• 5 Batista M C, Cartledge T P, Zellmer A W, Nieman L K, Merriam G R, Loriaux D L. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotrophin surge and ovulation.  J Clin Endocrinol Metab. 1992;  74 565-570
• 6 Gemzell-Danielsson K, Swahn M L, Westlund P, Johannisson E, Seppälä M, Bygdeman M. Effect of low daily doses of mifepristone on ovarian function and endometrial development.  Hum Reprod. 1997;  12 124-131
• 7 Liu J H, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen S S. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.  J Clin Endocrinol Metab. 1987;  65 1135-1140
• 8 Chen X L, Xiao B L. Effect of once weekly administration of mifepristone on ovarian function in normal women.  Contraception. 1997;  56 175-180
• 9 Croxatto H B, Salvatierra A M, Fuentealba B, Zurth C, Beier S. Effect of the antiprogestin onapristone on follicular growth in women.  Hum Reprod. 1994;  9 1442-1447
• 10 Stratton P, Hartog B, Hajizadeh N et al.. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women.  Hum Reprod. 2000;  15 1092-1099
• 11 Roblero L S, Croxatto H B. Effects of RU 486 on development and implantation of rat embryos.  Mol Reprod Dev. 1991;  29 342-346
• 12 Borman S M, Chwalisz K, Stouffer R L, Zelinski-Wooten M B. Chronic low-dose antiprogestin impairs preimplantation embryogenesis, but not oocyte nuclear maturation or fertilization in rhesus monkeys.  Steroids. 2003;  68 1041-1051
• 13 Heikinheimo O, Croxatto H, Salvatierra A M, Chang C C, Luukkainen T, Lahteenmaki P. Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans.  Hum Reprod. 1987;  2 645-648
• 14 Heikinheimo O, Kekkonen R, Lähteenmäki P. The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action.  Contraception. 2003;  68 421-426
• 15 Heikinheimo O, Kekkonen R. Dose-response relationship of RU 486.  Ann Med. 1993;  25 71-76
• 16 World Health Organization Task Force on Post-Ovulatory Methods of Fertility Regulation . Termination of pregnancy with reduced doses of mifepristone.  BMJ. 1993;  307 532-537
• 17 Passaro D P, Piquion J, Mullen N et al.. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.  Hum Reprod. 2003;  18 1820-1827
• 18 Brenner R M, Slayden O D, Critchley H O. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor.  Reproduction. 2002;  124 167-172
• 19 Marions L, Viski S, Gemzell-Danielsson K et al.. Contraceptive efficacy of daily administration of 0.5 mg mifepristone.  Hum Reprod. 1999;  14 2788-2790
• 20 Croxatto H B, Kovacs L, Massai R et al.. Effects of long-term low-dose mifepristone on reproductive function in women.  Hum Reprod. 1998;  13 793-798
• 21 Brown A, Cheng L, Lin S Q, Baird D. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.  J Clin Endocrinol Metab. 2002;  87 63-70
• 22 Gemzell-Danielsson K, Westlund P, Johannisson E, Swahn M L, Bygdeman M, Seppala M. Effect of low weekly doses of mifepristone on ovarian function and endometrial development.  Hum Reprod. 1996;  11 256-264
• 23 Marions L, Gemzell-Danielsson K, Swahn M L, Bygdeman M. Contraceptive efficacy of low doses of mifepristone.  Fertil Steril. 1998;  70 813-816
• 24 Spitz I M, Croxatto H B, Salvatierra A M, Heikinheimo O. Response to intermittent RU 486 in women.  Fertil Steril. 1993;  59 971-975
• 25 Godfrey E M, Mawson J T, Stanwood N L, Fielding S L, Schaff E A. Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study.  Contraception. 2004;  70 41-46
• 26 Cheng J, Weng L J, Han X J. Study on weekly low doses of mifepristone for contraception.  Chinese Journal of Obstetrics and Gynecology. 2001;  36 424-427
• 27 Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.  Fertil Steril. 1990;  53 747-750
• 28 Kekkonen R, Lähteenmäki P, Luukkainen T, Tuominen J. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.  Fertil Steril. 1993;  60 610-615
• 29 Kekkonen R, Croxatto H B, Lähteenmäki P, Salvatierra A M, Tuominen J. Effects of intermittent antiprogestin RU486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation.  Hum Reprod. 1995;  10 287-292
• 30 Croxatto H B, Massai M R, Salvatierra A M, Fuentealba B, Croxatto H D, Lähteenmäki P. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.  Contraception. 1996;  54 79-86
• 31 Croxatto H B, Salvatierra A M, Fuentealba B, Massai R. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women.  Hum Reprod. 1998;  13 3297-3302
• 32 Massai R, Forcelledo M L, Quinteros E, Fuentealba B, Croxatto H B. Anticoncepción oral libre de estrógenos: Regimen secuencial antiprogestina-progestina.  Cuban Journal of Public Health. 2003;  29(suppl 1) R104
• 33 Gemzell-Danielsson K, van Heusden A M, Killick S R et al.. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen.  Hum Reprod. 2002;  17 2588-2593
• 34 Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel.  Hum Reprod. 2000;  15 1969-1972
• 35 Massai M R, Pavez M, Fuentealba B, Croxatto H B, d'Arcangues C. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users.  Contraception. 2004;  70 47-54
• 36 Swahn M L, Johannisson E, Daniore V, de la Torre B, Bygdeman M. The effect of RU486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium.  Hum Reprod. 1988;  3 915-921
• 37 Gemzell K, Swahn M L, Bygdeman M. Regulation of non-pregnant human uterine contractility. Effect of antihormones.  Contraception. 1990;  42 323-335
• 38 Gemzell-Danielsson K, Swahn M L, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation.  Hum Reprod. 1993;  8 870-873
• 39 Hapangama D K, Brown A, Glasier A, Baird D T. Feasibility of administering mifepistone as a once a month contraceptive pill.  Hum Reprod. 2001;  16 1145-1150
• 40 Glasier A, Thong K J, Dewar M, Mackie M, Baird D T. Mifepristone compared with high-dose estrogen and progestogen for emergency postcoital contraception.  N Engl J Med. 1992;  327 1041-1044
• 41 Webb A MC, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception.  BMJ. 1992;  305 927-931
• 42 Ashok P W, Stalder C, Wagaarachchi P T, Flett G, Melvon L, Templeton A. A randomized study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception.  BJOG. 2002;  109 553-560
• 43 Croxatto H B, Salvatierra A M, Fuentealba B, Leiva L. Follicle stimulating hormone-granulosa cell axis involvement in the antifolliculotrophic effect of low dose mifepristone (RU486).  Hum Reprod. 1995;  10 1987-1991
• 44 Graham R A, Li T C, Seif M W, Aplin J D, Cooke I D. The effects of the antiprogesterone RU486 (Mifepristone) on an endometrial secretory glycan: an immunocytochemical study.  Fertil Steril. 1991;  55 1132-1136
• 45 Task Force on Postovulatory Methods of Fertility Regulation . Comparison of three single doses of mifepristone as emergency contraception: a randomized trial.  Lancet. 1999;  353 697-702
• 46 Xiao B L, von Hertzen H, Zhao H, Piaggio G. A randomized double-blind comparison of two single doses of mifepristone for emergency contraception.  Hum Reprod. 2002;  17 3084-3089
• 47 Piaggio G, Zhao H, von Hertzen H, Xiao B L, Cheng L. Combined estimates of effectiveness of mifepristone 10 mg in emergency contraception.  Contraception. 2003;  68 439-446
• 48 von Hertzen H, Piaggio G, Ding J H et al.. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial.  Lancet. 2002;  360 1803-1810
• 49 Cheng L, Gulmezoglu A M, Ezcurra E et al.. Interventions for emergency contraception.  Cochrane Database Syst Rev. 2004;  3 CD001324